# Estrigenix Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/estrigenix-therapeutics

- Industry: Pharmaceuticals
- Headquarters: Milwaukee, US
- Website: www.estrigenix.com/
- Total disclosed funding: $1.1M
- Latest round: Seed (Jul 21, 2026)
- Investors on record: 2

## About

Based in Wisconsin, US, and founded in 2018, Estrigenix Therapeutics, Inc., also known as Estrigenix, operates as a pharmaceutical company that offers drugs for menopausal women. The company was formed as a spin-out of the collaborative research of three Milwaukee area university scientists: William Donaldson (CEO), Karyn Frick (CSO), and Daniel Sem. In July 2026, Estrigenix Therapeutics, Inc. raised USD 2 million in seed funding led by Talents Fund.

Estrigenix offers novel therapeutics and pharmaceuticals that address the pressing medical needs of post-menopausal women by treating hot flashes and dementia, which commonly afflict women around the age of 50 during menopause. The company develops next-generation therapeutics, mainly estrogen-based products, with the help of patents like substituted (4-hydroxyphenyl)cyclohexane compounds and substituted (4-hydroxyphenyl)cycloalkane and (4-hydroxyphenyl)cycloalkene compounds. The company conducts estrogen-based research and undergoes clinical trials with its lead drug candidate, EGX358. The company will use the July 2026 funding to optimize lead candidates and complete preclinical development.

## Funding rounds

- Seed, Jul 21, 2026, $1M — Talents Fund
- Seed, May 7, 2022, $0.1M — CU Ventures

## Investors

- CU Ventures (https://capitalatlas.ai/funds/cu-ventures) — Seed
- Talents Fund (https://capitalatlas.ai/funds/talents-fund) — Seed